Overview

Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Status:
Unknown status

Trial end date:
2019-02-01

Target enrollment:
0

Participant gender:
All

Summary

The objectives of this study are to explore different dosing levels and schedules of entinostat in combination with pembrolizumab in patients with advanced solid tumors, in terms of safety, tolerability, pharmacokinetics (PK), impact on immune correlatives, and efficacy

Phase:

Phase 1

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Syndax Pharmaceuticals

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Entinostat
Histone Deacetylase Inhibitors
Pembrolizumab

Criteria

Inclusion Criteria:

1. Completed Study SNDX-275-0140 (NCT02897778)

2. Any AE or toxicity experienced in Study SNDX-275-0140 (NCT02897778) is resolved to
less than or equal to Grade 1

3. Continues to meet inclusion criteria for Study SNDX-275-0140 (NCT02897778) at the time
of entry into this study

Exclusion Criteria:

1. Completed Study SNDX-275-0140 (NCT02897778) more than 30 days prior to Cycle 1 Day 1
of this study

2. Continues to meet exclusion criteria for Study SNDX-275-0140 (NCT02897778) at the time
of entry into this study